|
|
||||||||
J Thorac Cardiovasc Surg 2009;138:527
© 2009 The American Association for Thoracic Surgery
Editorial |
Department of Anesthesiology, Emory University School of Medicine, Atlanta, Ga
Received for publication May 3, 2009; accepted for publication June 8, 2009. * Address for reprints: Ling Wei, MD, Professor, Department of Anesthesiology, 101 Woodruff Circle, Emory University School of Medicine, Atlanta, GA 30322. (Email: lwei7@emory.edu).
| The first 20% of the full text of this article appears below. |
As an emerging strategy of regenerative medicine, stem cell transplantation therapy has provided an exciting possibility for the treatments of many devastating diseases, including ischemic heart and brain disorders. For the clinical efficacy and efficiency to be fulfilled, however, a number of issues are still to be resolved in the potential cell-based therapy. The poor survival of transplanted cells (often 70%–90% death in a few days after transplantation) is one of the most critical dilemmas that have been seriously and specifically addressed in our recent investigations.1,2
Our article recently published in this Journal, titled "Transplantation of Hypoxia-Preconditioned Mesenchymal Stem Cells Improves Infarcted Heart Function via Enhanced Survival of Implanted Cells and Angiogenesis," demonstrated a markedly enhanced cell survival in
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |